Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving either cisplatin-based chemotherapy regimens or moderately emetogenic chemotherapy

被引：0
|
作者：
Annemans, L
Strens, D
Lox, E
Petit, C
Malonne, H
机构：
[1] Merck Sharp & Dohme bv, Brussels, Belgium
[2] HEDM IMS Hlth, Brussels, Belgium
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64638-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A107 / A108
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
    Moore, Susan
    Tumeh, John
    Wojtanowski, Steven
    Flowers, Christopher
    VALUE IN HEALTH, 2007, 10 (01) : 23 - 31
  • [2] Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy
    Molassiotis, Alex
    Nguyen, Allison Martin
    Rittenberg, Cynthia N.
    Makalinao, Alex
    Carides, Alexandra
    FUTURE ONCOLOGY, 2013, 9 (10) : 1443 - 1450
  • [3] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Takako Inoue
    Madoka Kimura
    Junji Uchida
    Kazumi Nishino
    Toru Kumagai
    Junko Taniguchi
    Fumio Imamura
    International Journal of Clinical Oncology, 2017, 22 : 600 - 604
  • [4] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Inoue, Takako
    Kimura, Madoka
    Uchida, Junji
    Nishino, Kazumi
    Kumagai, Toru
    Taniguchi, Junko
    Imamura, Fumio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 600 - 604
  • [5] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10): : E1870 - E1879
  • [6] Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium
    Annemans, Lieven
    Strens, Danielle
    Lox, Erica
    Petit, Christine
    Malonne, Hughes
    SUPPORTIVE CARE IN CANCER, 2008, 16 (08) : 905 - 915
  • [7] Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium
    Lieven Annemans
    Daniëlle Strens
    Erica Lox
    Christine Petit
    Hughes Malonne
    Supportive Care in Cancer, 2008, 16 : 905 - 915
  • [8] COST-EFFECTIVENESS OF PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY
    Rely, K.
    Pierre, K. A.
    Salinas, E. G.
    VALUE IN HEALTH, 2009, 12 (07) : A496 - A496
  • [9] Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Zelek, Laurent
    Navari, Rudolph
    Aapro, Matti
    Scotte, Florian
    CANCER MEDICINE, 2023, 12 (15): : 15769 - 15776
  • [10] Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    Warr, DG
    Hesketh, PJ
    Gralla, RJ
    Muss, HB
    Herrstedt, J
    Eisenberg, PD
    Raftopoulos, H
    Grunberg, SM
    Gabriel, M
    Rodgers, A
    Bohidar, N
    Klinger, G
    Hustad, CM
    Horgan, KJ
    Skobieranda, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2822 - 2830
12345